RJF Stock Overview
A pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products and specialties, as well as accessories authorized foodstuffs, dietary and personal care products, and cosmetics.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
No risks detected for RJF from our risk checks.
Laboratorio Reig Jofre, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.10 |
| 52 Week High | €3.38 |
| 52 Week Low | €2.15 |
| Beta | 0.92 |
| 11 Month Change | 14.81% |
| 3 Month Change | 10.32% |
| 1 Year Change | 38.39% |
| 33 Year Change | -25.12% |
| 5 Year Change | 29.71% |
| Change since IPO | -18.85% |
Recent News & Updates
Recent updates
Calculating The Fair Value Of Laboratorio Reig Jofre, S.A. (BME:RJF)
Jun 22
These 4 Measures Indicate That Laboratorio Reig Jofre (BME:RJF) Is Using Debt Extensively
Feb 02This Analyst Just Downgraded Their Laboratorio Reig Jofre, S.A. (BME:RJF) EPS Forecasts
Mar 07We Think Laboratorio Reig Jofre (BME:RJF) Is Taking Some Risk With Its Debt
Mar 07Laboratorio Reig Jofre (BME:RJF) Seems To Use Debt Quite Sensibly
May 17The Laboratorio Reig Jofre (BME:RJF) Share Price Has Gained 146%, So Why Not Pay It Some Attention?
Mar 07Is Laboratorio Reig Jofre (BME:RJF) Using Too Much Debt?
Jan 14Laboratorio Reig Jofre (BME:RJF) Shareholders Booked A 47% Gain In The Last Year
Dec 05Shareholder Returns
| RJF | ES Pharmaceuticals | ES Market | |
|---|---|---|---|
| 7D | 1.6% | 0.5% | 1.4% |
| 1Y | 38.4% | 15.0% | 29.3% |
Return vs Industry: RJF exceeded the Spanish Pharmaceuticals industry which returned 15.1% over the past year.
Return vs Market: RJF exceeded the Spanish Market which returned 27.6% over the past year.
Price Volatility
| RJF volatility | |
|---|---|
| RJF Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 2.9% |
| 10% most volatile stocks in ES Market | 5.4% |
| 10% least volatile stocks in ES Market | 0.6% |
Stable Share Price: RJF has not had significant price volatility in the past 3 months compared to the Spanish market.
Volatility Over Time: RJF's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 1,323 | Ignasi Reig | www.reigjofre.com |
Laboratorio Reig Jofre, S.A., a pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products and specialties, as well as accessories authorized foodstuffs, dietary and personal care products, and cosmetics. The company offers nutritional and parapharmacy products. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables and other products; specialty pharmacare products, which include skin, hair, nails, joint health and pain, and women’s health; and food supplements under the Forté Pharma brand.
Laboratorio Reig Jofre, S.A. Fundamentals Summary
| RJF fundamental statistics | |
|---|---|
| Market cap | €248.19m |
| Earnings (TTM) | €9.27m |
| Revenue (TTM) | €333.55m |
26.8x
P/E Ratio0.7x
P/S RatioIs RJF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RJF income statement (TTM) | |
|---|---|
| Revenue | €333.55m |
| Cost of Revenue | €146.60m |
| Gross Profit | €186.95m |
| Other Expenses | €177.69m |
| Earnings | €9.27m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 31, 2024
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 56.05% |
| Net Profit Margin | 2.78% |
| Debt/Equity Ratio | 25.3% |
How did RJF perform over the long term?
See historical performance and comparison